Cytokinetics Ends Tirasemtiv Program After Potential ALS Therapy Fails at Trial Goals
Expressing “profound disappointment” with tirasemtiv — their lead candidate for amyotrophic lateral sclerosis (ALS) — officials at Cytokinetics have ended development of the once-promising therapy. Robert I. Blum, president and chief executive officer of the San Francisco-based biotech, announced negative results for VITALITY-ALS (NCT02496767)…